Clinical trial · Interventional
Fluorescent Dyes for Lymph Node Mapping
Near-Infrared Imaging of Fluorescent Dyes for Lymph Node Mapping
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical research study is to find lymph nodes before surgery using a dye called indocyanine green (IC-Green). Objectives: 1. To determine the feasibility of using nonradioactive optical imaging techniques with indocyanine green (ICG) as a fluorescent contrast agent to identify all axillary lymph nodes. 2. To determine the feasibility of using nonradioactive optical imaging techniques with ICG as a fluorescent contrast agent to characterize lymphatic architecture and function in women with breast cancer who are scheduled for axillary node dissection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Indocyanine green (ICG) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- IC-Green Injections
- description
- ICG Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
- interventionNames
- Drug: Indocyanine green (ICG)
Primary outcomes (1)
- measure
- Percentage of Nodes Identified by ICG Among All Resected Lymph Nodes for Each Patient
- timeFrame
- Injection and Imaging procedure takes 1+ hour to complete
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects must be 18 years of age or older 2. Diagnosis of breast cancer requiring axillary nodal dissection 3. Negative urine pregnancy test within 72 hours prior to study drug administration, if female of childbearing potential 4. Females of childbearing potential who agree to use a medically accepted method of contraception for a period of one month following the study. Medically acceptable contraceptives include (i) hormonal contraceptives (such as birth control pills, Depo-Provera, or Lupron Depot) if such use is approved by the subject's Oncologist; (ii) barrier methods (such as a condom or diaphragm) used with a spermicide, or (iii) an intrauterine device (IUD). 5. Continuation of Inclusion #4: Non-childbearing potential is defined as physiologically incapable of becoming pregnant, including any female who is post-menopausal; postmenopausal is defined as the time after which a woman has experienced 12 consecutive months of amenorrhea (lack of menstruation). 6. Patients with a positive fine needle aspirate or core biopsy of their axillary nodes Exclusion Criteria: 1. Women who are pregnant or breast-feeding 2. Persons who are allergic to iodine 3. A female of child-bearing potential who does not agree to use an approved contraceptive for one month after study participation 4. History of ipsilateral axillary surgery including sentinel node biopsy 5. Any patient who does not meet inclusion criteria for study
References
Publications (0)
Data not yet available